DE69032007D1 - Leukozytenadhäsions-/endothelialzell-moleküle (elams) und moleküle wirksam bei leukozytenadhäsion (milas) - Google Patents
Leukozytenadhäsions-/endothelialzell-moleküle (elams) und moleküle wirksam bei leukozytenadhäsion (milas)Info
- Publication number
- DE69032007D1 DE69032007D1 DE69032007T DE69032007T DE69032007D1 DE 69032007 D1 DE69032007 D1 DE 69032007D1 DE 69032007 T DE69032007 T DE 69032007T DE 69032007 T DE69032007 T DE 69032007T DE 69032007 D1 DE69032007 D1 DE 69032007D1
- Authority
- DE
- Germany
- Prior art keywords
- molecules
- leucocyte adhesion
- elams
- milas
- endothelial cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/345,151 US5217870A (en) | 1989-04-28 | 1989-04-28 | Monoclonal antibodies against CDX |
US35951689A | 1989-06-01 | 1989-06-01 | |
US07/452,675 US5272263A (en) | 1989-04-28 | 1989-12-18 | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
PCT/US1990/002357 WO1990013300A1 (en) | 1989-04-28 | 1990-04-27 | ENDOTHELIAL CELL-LEUKOCYTE ADHESION MOLECULES (ELAMs) AND MOLECULES INVOLVED IN LEUKOCYTE ADHESION (MILAs) |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69032007D1 true DE69032007D1 (de) | 1998-03-05 |
Family
ID=27407673
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69032007T Expired - Lifetime DE69032007D1 (de) | 1989-04-28 | 1990-04-27 | Leukozytenadhäsions-/endothelialzell-moleküle (elams) und moleküle wirksam bei leukozytenadhäsion (milas) |
DE69034261T Expired - Lifetime DE69034261D1 (de) | 1989-04-28 | 1990-04-27 | Antikörper gegen VLA-4 |
DE69034204T Expired - Lifetime DE69034204T2 (de) | 1989-04-28 | 1990-04-27 | Leukozytenadhäsions-/Endothelialzell-Moleküle (ELAMs) und Moleküle wirksam bei Leukozytenadhäsion (MILAs) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69034261T Expired - Lifetime DE69034261D1 (de) | 1989-04-28 | 1990-04-27 | Antikörper gegen VLA-4 |
DE69034204T Expired - Lifetime DE69034204T2 (de) | 1989-04-28 | 1990-04-27 | Leukozytenadhäsions-/Endothelialzell-Moleküle (ELAMs) und Moleküle wirksam bei Leukozytenadhäsion (MILAs) |
Country Status (13)
Country | Link |
---|---|
US (4) | US5272263A (de) |
EP (3) | EP0458911B1 (de) |
JP (6) | JPH04502859A (de) |
KR (3) | KR100186800B1 (de) |
AT (3) | ATE162720T1 (de) |
AU (1) | AU638041B2 (de) |
CA (1) | CA2031518C (de) |
DE (3) | DE69032007D1 (de) |
DK (2) | DK0807683T3 (de) |
ES (1) | ES2249791T3 (de) |
MX (1) | MX9203137A (de) |
NO (1) | NO905553L (de) |
WO (1) | WO1990013300A1 (de) |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776775A (en) * | 1989-02-21 | 1998-07-07 | Dana-Farber Cancer Institute | Anti-LAM 1-3 antibody and hybridoma |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
US6307025B1 (en) * | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
EP0583799A1 (de) * | 1989-05-23 | 1994-02-23 | Otsuka Pharmaceutical Co., Ltd. | Monoklonale Antikörper gegen das auf der Oberfläche der aktivierten endothelialen Zellen antigenischen Sialoglykoprotein |
US7238668B1 (en) | 1989-09-01 | 2007-07-03 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof |
US5730978A (en) * | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US20040142899A1 (en) * | 1990-01-11 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US5595900A (en) * | 1990-02-14 | 1997-01-21 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
WO1991013085A1 (en) * | 1990-03-02 | 1991-09-05 | Brigham And Women's Hospital | Mononuclear leukocyte directed endothelial adhesion molecule associated with atherosclerosis |
JPH05501359A (ja) * | 1990-04-27 | 1993-03-18 | バイオジェン,インコーポレイテッド | 付着分子発現に関与するフコシルトランスフェラーゼ |
WO1991019501A1 (en) * | 1990-06-15 | 1991-12-26 | Cytel Corporation | Intercellular adhesion mediators |
US5576305A (en) * | 1990-06-15 | 1996-11-19 | Cytel Corporation | Intercellular adhesion mediators |
US5753631A (en) * | 1990-06-15 | 1998-05-19 | Cytel Corporation | Intercellular adhesion mediators |
US6387884B1 (en) | 1990-06-18 | 2002-05-14 | Stanford University | Leukocyte homing modulation |
US6391857B1 (en) | 1990-06-18 | 2002-05-21 | Stanford University | Methods and compositions for endothelial binding |
DK162890D0 (da) * | 1990-07-06 | 1990-07-06 | Novo Nordisk As | Polypeptid |
US5211936A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a cite of inflammation utilizing elam-1 ligands site |
US5143712A (en) * | 1990-07-30 | 1992-09-01 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5211937A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5648344A (en) * | 1990-07-30 | 1997-07-15 | Glycomed Incorporated | Methods of treating inflammation using selection binding compounds |
US7449186B1 (en) | 1990-08-02 | 2008-11-11 | Fred Hutchinson Cancer Research Center | Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies |
US5827670A (en) * | 1990-08-02 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies |
US5843738A (en) * | 1990-08-14 | 1998-12-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
CA2089563C (en) * | 1990-08-14 | 2004-04-06 | Clarence Frank Bennett | Oligonucleotide modulation of cell adhesion |
NZ240316A (en) * | 1990-10-25 | 1996-12-20 | Univ Michigan | Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells |
IE914075A1 (en) * | 1990-11-23 | 1992-06-03 | Gen Hospital Corp | Inhibition of cell adhesion protein-carbohydrate¹interactions |
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
EP0568631A4 (de) * | 1991-01-24 | 1995-04-05 | Cytel Corp | Monoklonale antikörper gegen elam-1 und deren verwendungen. |
US5807745A (en) * | 1991-03-11 | 1998-09-15 | New England Medical Center Hospitals, Inc. | Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component |
CA2108786A1 (en) * | 1991-04-19 | 1992-10-20 | John L. Magnani | Compositions and methods for endothelial binding |
US6121233A (en) | 1991-04-19 | 2000-09-19 | John L. Magnani | Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
AU667813B2 (en) * | 1991-05-03 | 1996-04-18 | Rockefeller University, The | Amino-acid sequence homologies between selectins and B pertussis toxin-peptides derived therefrom antibodies thereto pharmaceutical compositions |
JP3859697B2 (ja) * | 1991-05-06 | 2006-12-20 | ジェネンテック・インコーポレーテッド | セレクチンリガンド |
US5318890A (en) * | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
US5891841A (en) * | 1991-06-11 | 1999-04-06 | The Center For Blood Research, Inc. | Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof |
GB9120768D0 (en) * | 1991-09-30 | 1991-11-13 | British Bio Technology | Diagnostic and prognastic materials and methods |
GB9120767D0 (en) * | 1991-09-30 | 1991-11-13 | British Bio Technology | Diagnostic and prognostic materials and methods |
US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
US5700658A (en) * | 1992-01-27 | 1997-12-23 | Icos Corporation | ICAM-4 materials and methods |
US5852170A (en) * | 1992-01-27 | 1998-12-22 | Icos Corporation | ICAM-4 materials and methods |
US5702917A (en) * | 1992-01-27 | 1997-12-30 | Icos Corporation | Polynucleotides encoding human ICAM-4 |
US5525487A (en) * | 1992-01-27 | 1996-06-11 | Icos Corporation | DNA encoding I-CAM related protein |
US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
US6153395A (en) * | 1992-01-27 | 2000-11-28 | Icos Corporation | ICAM-related protein |
US6100383A (en) * | 1992-01-27 | 2000-08-08 | Icos Corporation | Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions |
US6818743B1 (en) | 1992-01-27 | 2004-11-16 | Icos Corporation | I-CAM related protein |
US5880268A (en) * | 1992-01-27 | 1999-03-09 | Icos Corporation | Modulators of the interaction between ICAM-R and αd /CD18 |
WO1993014776A1 (en) * | 1992-01-27 | 1993-08-05 | Icos Corporation | Icam-related protein |
US5989843A (en) * | 1992-01-27 | 1999-11-23 | Icos Corporation | Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein |
US5773293A (en) * | 1992-01-27 | 1998-06-30 | Icos Corporation | Anti-ICAM-4 antibodies and hybridomas |
US5753502A (en) * | 1993-08-05 | 1998-05-19 | Icos Corporation | Neuron-specific ICAM-4 promoter |
US5532127A (en) * | 1992-01-27 | 1996-07-02 | Icos Corporation | Assay for 1-CAM related protein expression |
US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
ES2193143T3 (es) * | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
EP0786522A2 (de) * | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen |
US5596090A (en) * | 1992-07-24 | 1997-01-21 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human VCAM-1 RNA |
US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
NZ299210A (en) * | 1992-09-02 | 2000-08-25 | Isis Pharmaceuticals Inc | Treating diseases characterised by changes in intercellular adhesion molecules using coding sequences hybridizable with those encoding proteins involved in synthesis of such molecules |
DE69419721T2 (de) * | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
US5412123A (en) * | 1993-02-08 | 1995-05-02 | Glycomed Incorporated | Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system |
AU687790B2 (en) * | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
US5789385A (en) * | 1993-06-16 | 1998-08-04 | Glycomed Incorporated | Sialyl Lewisx mimetics containing phenyl backbones |
US5837689A (en) * | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5658880A (en) * | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5508387A (en) * | 1993-08-04 | 1996-04-16 | Glycomed Incorporated | Selectin binding glycopeptides |
EP0728205B1 (de) * | 1993-11-12 | 2002-10-16 | Ribozyme Pharmaceuticals, Inc. | Reagenz zur behandlung von arthritischen zustaenden |
US5677291A (en) * | 1993-12-10 | 1997-10-14 | Hoechst Marion Roussel, Inc. | Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols |
US6884590B1 (en) | 1994-02-11 | 2005-04-26 | Cedars-Sinai Medical Center | Methods of screening for ulcerative colitis and crohn's disease |
US5681699A (en) * | 1994-02-11 | 1997-10-28 | Cedars-Sinai Medical Center | Methods of diagnosing ulcerative colitis and Crohn's disease |
US5691180A (en) * | 1994-06-09 | 1997-11-25 | The Regents Of The University Of Michigan | DNA sequence encoding N-acetyl-galactosamine-transferase |
US6152141A (en) * | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
US5807732A (en) * | 1995-02-28 | 1998-09-15 | Lowe; John B. | GDP-L-fucose: β-D-galactoside 2-α-L-fucosyltransferases, DNA sequences encoding the same, method for producing the same and a method of genotyping a person |
ATE346920T1 (de) * | 1995-06-20 | 2006-12-15 | Roche Diagnostics Gmbh | Neues immunoregulatorisches protein lst-1 |
EP0750039A1 (de) * | 1995-06-20 | 1996-12-27 | Boehringer Mannheim Gmbh | Immunoregulatorive Proteine LST-1 |
US5770420A (en) * | 1995-09-08 | 1998-06-23 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
US6033663A (en) * | 1996-04-10 | 2000-03-07 | Neose Technologies, Inc. | Nucleic acids encoding GDP-Fucose pyrophosphorylase |
US5795876A (en) * | 1996-04-30 | 1998-08-18 | Hoechst Marion Rousssel, Inc. | Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols |
US5608095A (en) * | 1996-04-30 | 1997-03-04 | Hoechst Marion Roussel, Inc. | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
US6960656B1 (en) | 1996-10-25 | 2005-11-01 | Cedars Sinai Medical Center | Nucleic acid encoding DS-CAM proteins and products related thereto |
US6114572A (en) * | 1996-11-20 | 2000-09-05 | Hoechst Marion Roussel, Inc. | Substituted phenols and thiophenols useful as antioxidant agents |
US6121463A (en) * | 1997-06-24 | 2000-09-19 | Hoechst Marion Roussel, Inc. | Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents |
US6133467A (en) * | 1997-06-25 | 2000-10-17 | Hoechst Marion Roussel, Inc. | 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol |
EP2324857A1 (de) | 1997-09-08 | 2011-05-25 | The General Hospital Corporation | Vorbereitung zur schnelle Bilddarstellung von cardiovaskulare Erkrankungen |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
JP2002520297A (ja) | 1998-07-13 | 2002-07-09 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | アミノリン脂質に結合する治療結合体を用いる癌処置方法 |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
PL203114B1 (pl) | 1998-09-14 | 2009-08-31 | Regents Board Of | Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1 |
US7618630B2 (en) * | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
IL142958A0 (en) | 1998-12-18 | 2002-04-21 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
CA2349333A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP1741428A3 (de) | 1999-08-13 | 2007-05-09 | Biogen Idec MA, Inc. | Hemmer der Zelladhäsion |
DK1214091T3 (da) * | 1999-09-14 | 2006-08-28 | Biogen Idec Inc | Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister |
JP2001104636A (ja) * | 1999-10-04 | 2001-04-17 | Shinsedai Kk | 体感ボールゲーム装置 |
US20060115473A1 (en) * | 2000-12-14 | 2006-06-01 | Biogen Idec Ma Inc., A Massachusetts Corporation | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
US20020004247A1 (en) * | 1999-12-23 | 2002-01-10 | Genentech, Inc. | Assay method |
JP3459609B2 (ja) * | 2000-03-17 | 2003-10-20 | 三洋電機株式会社 | ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法 |
HUP0300810A2 (hu) * | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
US7491506B2 (en) * | 2001-06-21 | 2009-02-17 | The Regents Of The University Of California | Inhibition of B-cell maturation and antibody production |
WO2003019136A2 (en) * | 2001-08-06 | 2003-03-06 | The Regents Of The University Of California | Methods for inhibiting angiogenesis |
CA2468125A1 (en) * | 2001-10-24 | 2003-05-01 | Dgi Biotechnologies, Inc. | Target specific screening and its use for identifying target binders |
US20030191075A1 (en) * | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
JP2007509042A (ja) * | 2003-09-29 | 2007-04-12 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 造血前駆細胞の接着、分化および遊走を変化させるための方法 |
US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
CN103169965A (zh) * | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
US8329186B2 (en) * | 2004-12-20 | 2012-12-11 | Isu Abxis Co., Ltd | Treatment of inflammation using BST2 inhibitor |
US20080299128A1 (en) * | 2006-06-20 | 2008-12-04 | Myung Kim | Effect of Bst2 on inflammation |
US7740856B2 (en) * | 2005-12-20 | 2010-06-22 | Isu Abxis Co., Ltd. | Effect of BST2 on inflammation |
DK2264043T3 (da) | 2005-09-02 | 2018-01-29 | Glycomimetics Inc | Heterobifunktionelle pan-selektin-inhibitorer |
US20110034396A1 (en) * | 2005-09-28 | 2011-02-10 | Biovascular, Inc. | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions |
US7691839B2 (en) | 2005-09-28 | 2010-04-06 | Biovascular, Inc. | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
WO2007092471A2 (en) * | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
US8486640B2 (en) | 2007-03-21 | 2013-07-16 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease |
DK2217329T3 (en) * | 2007-11-07 | 2018-04-23 | Anthrogenesis Corp | APPLICATION OF NAVLINE BLOOD IN THE TREATMENT OF COMPLIANCES IN CONNECTION WITH PREGNANCY BIRTH |
US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
WO2010075579A2 (en) | 2008-12-24 | 2010-07-01 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy |
MX2011010971A (es) * | 2009-04-17 | 2012-01-19 | Biogen Idec Inc | Composiciones y metodos para tratar leucemia mielogena aguda. |
US8709801B2 (en) | 2009-12-29 | 2014-04-29 | Taipei Medical University | Kit and method for the capture of tumor cells |
TWI474000B (zh) * | 2009-12-30 | 2015-02-21 | Univ Taipei Medical | 捕捉腫瘤細胞之套組及方法 |
AU2011239512B2 (en) | 2010-04-16 | 2016-01-21 | Biogen Ma Inc. | Anti-VLA-4 antibodies |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
EP2688585B1 (de) * | 2011-03-23 | 2018-09-05 | The Regents of The University of California | Verfahren und zusammensetzungen zur verbesserung einer antiangiogentherapie mit antiintegrinen |
KR102055958B1 (ko) | 2011-12-22 | 2019-12-13 | 글리코미메틱스, 인크. | E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법 |
US9867841B2 (en) | 2012-12-07 | 2018-01-16 | Glycomimetics, Inc. | Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells |
KR20210157418A (ko) | 2013-03-27 | 2021-12-28 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
EP4105236A1 (de) | 2013-07-19 | 2022-12-21 | Cedars-Sinai Medical Center | Anti-tl1a (tnfsf15) antikörper zur behandlung von entzündlichen darmerkrankungen |
JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス, インコーポレイテッド | E−セレクチンおよびcxcr4ケモカイン受容体のヘテロ二官能性阻害剤 |
US10947311B2 (en) | 2015-11-20 | 2021-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | VCAM-1 mediated methods and compositions for treating aging-associated impairments |
CA3009836A1 (en) | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
EP3430172A4 (de) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | Verfahren zur diagnose einer entzündlichen darmerkrankung durch rnaset2 |
EP3497131B1 (de) | 2016-08-08 | 2022-03-09 | GlycoMimetics, Inc. | Kombination von t-zell-checkpoint-inhibitoren mit e-selectin- oder cxcr4-inhibitoren oder mit heterobifunktionellen e-selectin- wie auch cxcr4-inhibitoren |
KR102607640B1 (ko) | 2016-10-07 | 2023-11-28 | 글리코미메틱스, 인크. | 매우 강력한 다량체성 e-셀렉틴 길항물질 |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
EP3717013A1 (de) | 2017-11-30 | 2020-10-07 | GlycoMimetics, Inc. | Verfahren zur mobilisierung von knochenmarkinfiltrierenden lymphozyten und deren verwendung |
AU2018395417B2 (en) | 2017-12-29 | 2023-07-13 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
CA3091454A1 (en) | 2018-03-05 | 2019-09-12 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
IL294921A (en) | 2020-01-24 | 2022-09-01 | Pfizer | Antibodies against E-selectin, preparations and methods of use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769320A (en) * | 1982-07-27 | 1988-09-06 | New England Medical Center Hospitals, Inc. | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations |
US4752569A (en) | 1984-06-21 | 1988-06-21 | The Regents Of The University Of California | Sialylated Lewisx epitope, antibodies and diagnosis |
US4783330A (en) * | 1984-11-15 | 1988-11-08 | New England Medical Center Hospitals, Inc. | Monoclonal antibodies to activated platelets |
DE3642096A1 (de) * | 1986-12-10 | 1988-06-16 | Boehringer Ingelheim Int | Pferde-(gamma)-interferon |
US5284931A (en) * | 1987-05-04 | 1994-02-08 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US4865971A (en) * | 1987-06-30 | 1989-09-12 | Coulter Corporation | Monoclonal antibody specific to a common determinant site of neutrophils and eosinophils |
US5019648A (en) * | 1987-07-06 | 1991-05-28 | Dana-Farber Cancer Institute | Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein |
EP0330506A3 (de) * | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | VLA-Proteine |
US5081034A (en) * | 1988-11-14 | 1992-01-14 | Brigham & Women's Hospital | Cloned genes which encode elam-1 |
US5821340A (en) * | 1989-02-14 | 1998-10-13 | Brigham & Women's Hospital | Inducible endothelial surface protein mediating lymphoid and tumor cell adhesion: antibodies and uses |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5098833A (en) * | 1989-02-23 | 1992-03-24 | Genentech, Inc. | DNA sequence encoding a functional domain of a lymphocyte homing receptor |
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
EP0583799A1 (de) * | 1989-05-23 | 1994-02-23 | Otsuka Pharmaceutical Co., Ltd. | Monoklonale Antikörper gegen das auf der Oberfläche der aktivierten endothelialen Zellen antigenischen Sialoglykoprotein |
US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
-
1989
- 1989-12-18 US US07/452,675 patent/US5272263A/en not_active Expired - Lifetime
-
1990
- 1990-04-27 DE DE69032007T patent/DE69032007D1/de not_active Expired - Lifetime
- 1990-04-27 AT AT90911366T patent/ATE162720T1/de not_active IP Right Cessation
- 1990-04-27 WO PCT/US1990/002357 patent/WO1990013300A1/en active Application Filing
- 1990-04-27 AT AT05017737T patent/ATE419275T1/de not_active IP Right Cessation
- 1990-04-27 DK DK97108263T patent/DK0807683T3/da active
- 1990-04-27 EP EP90911366A patent/EP0458911B1/de not_active Expired - Lifetime
- 1990-04-27 AT AT97108263T patent/ATE305038T1/de not_active IP Right Cessation
- 1990-04-27 EP EP97108263A patent/EP0807683B8/de not_active Expired - Lifetime
- 1990-04-27 AU AU60492/90A patent/AU638041B2/en not_active Expired
- 1990-04-27 EP EP05017737A patent/EP1616883B1/de not_active Expired - Lifetime
- 1990-04-27 ES ES97108263T patent/ES2249791T3/es not_active Expired - Lifetime
- 1990-04-27 MX MX9203137A patent/MX9203137A/es active IP Right Grant
- 1990-04-27 CA CA002031518A patent/CA2031518C/en not_active Expired - Lifetime
- 1990-04-27 DE DE69034261T patent/DE69034261D1/de not_active Expired - Lifetime
- 1990-04-27 KR KR1019980706780A patent/KR100186800B1/ko not_active IP Right Cessation
- 1990-04-27 JP JP2510560A patent/JPH04502859A/ja active Pending
- 1990-04-27 DK DK05017737T patent/DK1616883T3/da active
- 1990-04-27 DE DE69034204T patent/DE69034204T2/de not_active Expired - Lifetime
- 1990-12-21 NO NO90905553A patent/NO905553L/no unknown
- 1990-12-28 KR KR1019900702704A patent/KR100214156B1/ko not_active IP Right Cessation
-
1993
- 1993-03-23 US US08/035,674 patent/US5367056A/en not_active Expired - Lifetime
-
1994
- 1994-09-22 US US08/310,890 patent/US6252043B1/en not_active Expired - Lifetime
-
1998
- 1998-12-09 KR KR1019980710064A patent/KR100214155B1/ko not_active IP Right Cessation
-
1999
- 1999-07-26 JP JP21141499A patent/JP3408773B2/ja not_active Expired - Lifetime
-
2001
- 2001-06-18 JP JP2001184133A patent/JP3513496B2/ja not_active Expired - Lifetime
-
2002
- 2002-05-13 JP JP2002137850A patent/JP3525128B2/ja not_active Expired - Lifetime
- 2002-12-27 JP JP2002381188A patent/JP3684228B2/ja not_active Expired - Lifetime
-
2003
- 2003-10-07 JP JP2003348879A patent/JP2004099616A/ja active Pending
-
2006
- 2006-06-06 US US11/447,664 patent/US20070149769A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69032007D1 (de) | Leukozytenadhäsions-/endothelialzell-moleküle (elams) und moleküle wirksam bei leukozytenadhäsion (milas) | |
PT907735E (pt) | Moduladores da regeneracao de tecidos | |
ATE239789T1 (de) | Chimäre prokoagulierende proteine | |
CA2141803A1 (en) | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen | |
RU95110871A (ru) | Способы определения нуклеотидной последовательности | |
ATE46718T1 (de) | Hybride menschliche leukozyten-interferone, verfahren zu deren mikrobieller herstellung, zwischenverbindungen dafuer und dieselben enthaltende zusammensetzungen. | |
DE59510905D1 (de) | Hochmolekulare und niedermolekulare Fraktionen des von Willebrand-Faktors | |
DE69333346T2 (de) | Neuartiges p- selectin ligandenprotein | |
ES2170747T3 (es) | Analogos superiores de trombomodulina para uso farmaceutico. | |
ES2171563T3 (es) | Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica. | |
CA2138793A1 (en) | Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections | |
DE3780357D1 (de) | Plasminogen-aktivator und thrombolytische zusammensetzung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |